The principal goal of his research is to increase the impact of proteomics on the basic sciences and the clinical sciences, with an emphasis on translational research leading to direct impact on patient care. This is accomplished by applying current state-of-the-art proteomic technologies to collaborations with PIs from the School of Medicine, addressing their research needs, along with original research which increases the information content from each proteomic experiment.
The principal focus of his personal research is dedicated to not only increasing the information content within each proteomic experiment, but addresses improvements in methods for data collection which enable the creation of databases of not only qualitative identifications, but also of differential expression proteomics information (relative expression and absolute (molar) expression).
The use of an optimized, systematic, and standardized approach to data collection in proteomic experiments permits the direct comparison of results across experiments, across projects, and across laboratories. A database of quantitative and qualitative information which allows such comparisons will help transform proteomics from the current 'one-off' approach into a systems biology tool. The use of a systematic approach to data collection and the population of a quantitative and qualitative proteomics database will significantly enhance our ability to translate proteomic results from basic science experiments into patient care – rapidly moving from bench to bedside. These research goals require multi-disciplinary research projects spanning the fields of analytical chemistry, bioinformatics, statistics, and biology, thus success in this research requires a high degree of collaboration between very diverse scientific fields. It requires the ability to not only collect large volumes of proteomics LC/MS data in a systematic manner, but to be able to efficiently organize the data, align the data, and mine the data in a statistically significant manner. The Duke Center for Genomic and Computational Biology provides an environment ideal for this type of research, as the Institute was designed as an integrated interdisciplinary network of centers.
Arthur Moseley is the Director of Proteomics for the School of Medicine at Duke University. In this position he is responsible for the development and application of proteomic technologies for open (unbiased) qualitative and quantitative UPLC/MS/MS analyses using high resolution, accurate mass tandem mass spectrometers coupled with ultra-performance nanoscale capillary liquid chromatographs, and for targeted protein quantitation using UPLC/MS/MS with multiple reaction monitoring (MRM).
The Proteomics Core Facility has the capability for support a diverse range of research projects, from studies in Basic Sciences Departments through support of clinical trials for Clinical Sciences Departments. The clinical support has included biomarker discovery in studies in the areas of oncology, immunology, and infectious disease. Prior to his position at Duke University, he managed mass spectrometry laboratories at GSK for sixteen years, and for the last six years of these years he lead a transnational laboratory (US/UK) dedicated to proteomic biomarker discovery. Dr. Moseley received his MS in Physical Chemistry from North Carolina State University, and his PhD in Analytical Chemistry from the University of North Carolina at Chapel Hill. His dissertation, under the direction of Professor Jim Jorgenson, addressed the coupling of nanoscale separation with tandem mass spectrometry for the analysis of peptides and proteins.